ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Otsuka and Sumitomo Pharma side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

OtsukaSumitomo Pharma
studies on the registry784273
open to participants now579
phase 3 studies under way312
reach primary completion within a year244
programswith a study of their own in two years254

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseOtsukaSumitomo Pharma
Phase 1

Otsuka: 12 of its 25 programs at phase 1

  1. SEP-380135phase 1
  2. VIS171phase 1
  3. 1-(12-(1 CARBOXYCYCLOPROPYL)DODECYL)CYCLOPROPANE-1-CARBOXYLIC acidphase 1
  4. ARC-02phase 1
  5. HBM7020phase 1

and 7 more — sign in to see them all

48%
00%
Phase 2

Otsuka: 2 of its 25 programs at phase 2

  1. VIS954phase 2
  2. OPC 131461phase 2
8%

Sumitomo Pharma: 4 of its 4 programs at phase 2

  1. nuvisertibphase 2
  2. enzomenibphase 2
  3. DSP-1083phase 2
  4. DSP-3077phase 2
100%
Phase 3

Otsuka: 10 of its 25 programs at phase 3

  1. sibeprenlimabphase 3
  2. ulotarontphase 3
  3. centanafadine hydrochloridephase 3
  4. futibatinibphase 3
  5. repinatrabitphase 3

and 5 more — sign in to see them all

40%
00%
Approved, new studies

Otsuka: 1 of its 25 programs at approved, new studies

  1. Tolvaptanapproved, new study
4%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Otsuka9 readouts · 3 phase 3·

Otsuka, Dec ’26: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. difamilastphase 3 · Dec 0 · NCT07173478
  2. futibatinibphase 3 · Dec 0 · NCT05727176
  3. SEP-380135phase 1 · Dec 2 · NCT07455084
·

Otsuka, Feb ’27: 1 program whose next study reaches primary completion

  1. repinatrabitphase 3 · Feb 9 · NCT07713758

Otsuka, Mar ’27: 1 program whose next study reaches primary completion

  1. sibeprenlimabphase 3 · Mar 13 · NCT06928142
·

Otsuka, May ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. centanafadine hydrochloridephase 3 · May 27 · NCT07759154
  2. zipalertinibphase 3 · May 27 · NCT05973773

Otsuka, Jun ’27: 1 program whose next study reaches primary completion

  1. zimberelimabphase 3 · Jun 0 · NCT04999761
·

Otsuka, Aug ’27: 1 program whose next study reaches primary completion

  1. 1-(12-(1 CARBOXYCYCLOPROPYL)DODECYL)CYCLOPROPANE-1-CARBOXYLIC acidphase 1 · Aug 25 · NCT07525960
··
Sumitomo Pharma2 readouts · 0 phase 3·····

Sumitomo Pharma, Apr ’27: 1 program whose next study reaches primary completion

  1. nuvisertibphase 2 · Apr 30 · NCT04176198
·

Sumitomo Pharma, Jun ’27: 1 program whose next study reaches primary completion

  1. enzomenibphase 2 · Jun 30 · NCT04988555
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Otsuka

New programs 0

None

Reached a new phase 1

  • VIS954phase 2 · Oct 23 · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Study stopped 0

None

Primary completion later 3

Sumitomo Pharma

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 1 in all. A program counts in each condition its studies name most.

ConditionOtsukaSumitomo Pharma
Parkinson Diseaseboth · compare here

Otsuka in Parkinson Disease: 1 program

  1. ulotarontphase 3

Their studies: Otsuka’s studies of Parkinson Disease in search

Sumitomo Pharma in Parkinson Disease: 1 program

  1. DSP-1083phase 2

Their studies: Sumitomo Pharma’s studies of Parkinson Disease in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Otsuka 7 of 25 · Sumitomo Pharma 1 of 4 programs (8 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.